Squeezing life into botulinum toxin A in migraine: imploding versus exploding pain

Affiliations

Editorial

Peter J Goadsby. Pain. 2006.

. 2006 Dec 5;125(3):206-207.

doi: 10.1016/j.pain.2006.10.001. Epub 2006 Oct 25.

¹ Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

No abstract available

Comment on

Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.
Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Jakubowski M, et al. Pain. 2006 Dec 5;125(3):286-295. doi: 10.1016/j.pain.2006.09.012. Epub 2006 Oct 25. Pain. 2006. PMID: 17069972 Free PMC article. Clinical Trial.

1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785-793.
1. Brin MF, Swope DM, O'Brien C, Abbasi S, Pgoda JM. Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia. 2000;20:421-422.
1. Chankrachang S, Arayawichanont A, Poungvarin N. Botulinum toxin type A in migraine without aura prophylaxis:a 12 week prospective, multicentre, double-blin, randomized, placebo-controlled trial. Cephalalgia. 2005;25:992-993.
1. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-133.
1. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005;45:315-324.